is an ovarian stimulator and selective estrogen receptor modulator. This drug increases the amount of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secreted by the pituitary gland, thus inducing ovulation for women who have infrequent or absent menstrual periods. Health care providers use it for the treatment of ovulatory failure in women who have tried to become pregnant but have failed. Ovulation occurs 5 to 10 days after the course of clomiphene treatment has been completed. Prior to beginning the drug regimen, the nurse instructs the woman about taking her basal temperature 5 to 10 days following administration. An incremental rise in temperature is an indication that ovulation has recently occurred.
Clomiphene is a mixture of zuclomiphene and enclomiphene. Metabolized by the liver, the drug has a half-life of 5 days. It is excreted in the feces and urine.
Possible adverse effects of clomiphene include ovarian enlargement, hot flashes, breast pain and tenderness, and uterine bleeding. Some women have reported visual disturbances, abdominal discomfort, and headaches. Contraindications include liver disease, thyroid or adrenal disease, intracranial lesions, ovarian cysts, and abnormal uterine bleeding.